Tianjin Pharma's Indonesian JV a stepping stone to international expansion

While many big Chinese pharma companies are looking at the US market to take their first international steps, Tianjin Pharma, a state-owned group and the local partner in GlaxoSmithKline's joint venture in China, has decided to begin its planned global expansion in Southeast Asia.

The firm has entered into a joint venture in Indonesia with Jakarta-based Kimia Farma and another local firm, Tigaka Distrinto. The three companies will jointly invest $27.7 million to build a production facility in Cikarang, Java, in which Tianjin Pharma will own 46% of the shares